Q4 2025 Caris Life Sciences Inc Earnings Call Transcript
Key Points
- Caris Life Sciences Inc (CAI) reported a record-breaking quarter with total revenues increasing 125% year over year to $293 million.
- The company's molecular profiling services revenues increased by 199% year over year, reaching $282 million in Q4 2025.
- Caris Life Sciences Inc (CAI) achieved a positive GAAP net income of $82 million and adjusted EBITDA of $106 million, marking the third consecutive quarter of positive adjusted EBITDA and free cash flow.
- The company's balance sheet strengthened with cash on hand growing to slightly above $800 million, an increase of $43 million in the quarter.
- Caris Life Sciences Inc (CAI) plans to launch a revolutionary cancer early detection test, Caris Detect, which has the potential to significantly impact cancer mortality rates.
- Pharma R&D Services revenues were relatively low at $10.8 million in the fourth quarter.
- The company faces challenges in maintaining high specificity in its early detection tests due to the high-risk nature of the control population.
- There is uncertainty regarding the impact of new sales hires on revenue and volume growth, as the company has not incorporated potential benefits into its 2026 guidance.
- The company's guidance for 2026 includes a significant increase in operating expenses, primarily driven by commercial expansion and pipeline trial activities.
- Caris Life Sciences Inc (CAI) has not provided a specific range for adjusted EBITDA for 2026, indicating potential variability in financial performance due to planned investments.
Good afternoon, everyone, and welcome to the Caris Life Sciences Q4 2025 earnings call. My name is Dana, and I will be your coordinator today. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker, Russ Denton. Please go ahead.
Thank you. Earlier today, Caris Life Sciences released financial results for the quarter and year ended December 31, 2025. Joining the call from Caris today are David Dean Halbert, our Founder, Chairman and CEO; David Spetzler, our President; Brian Brille, our Vice Chairman and EVP; Bobby Hill, our Chief Commercial Officer; and Luke Power, our CFO.
Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
